The earnings call highlighted several strong achievements, such as achieving profitability, significant membership growth, and improved star ratings. However, there were concerns regarding increased SG&A expenses and the impact of minimum MLR rebates on revenue. Overall, the positive aspects outweighed the challenges.

Company Guidance

During the Clover Health fourth quarter and full-year 2024 earnings call, the company provided several key metrics and guidance for the future. Clover Health reported a meaningful full-year adjusted EBITDA profitability and surpassed 100,000 Medicare Advantage members during the annual enrollment period (AEP), reflecting a 27% year-over-year growth and a 95% retention rate. The company also improved its star ratings, with over 95% of members in four-star rated plans. For 2025, Clover Health expects insurance revenue between $1.8 billion and $1.875 billion, driven by a 30% growth in average Medicare Advantage membership, expected to range between 103,000 and 107,000 members. The guidance also includes adjusted SG&A between $355 million and $365 million, and adjusted EBITDA between $45 million and $70 million. Additionally, Clover Health highlighted its successful launch of Counterpart Health, its software business, and plans to invest in expanding its home care services and Clover Assistant technology.

Achieved Adjusted EBITDA Profitability

Clover Health achieved full year adjusted EBITDA profitability in 2024, marking a significant milestone in its financial performance.

Medicare Advantage Membership Growth

The company surpassed 100,000 Medicare Advantage members during AEP, reflecting a 27% year-over-year growth and a 95% AEP retention rate.

Improved Star Ratings

Over 95% of members are now in four-star rated PPO plans, with nation-leading clinical measures, setting the stage for higher benchmarks in 2026.

Counterpart Health Launch

Successfully launched Counterpart Health, implementing first external partnerships and establishing a pipeline of potential customers.

Revenue Growth

Insurance revenue grew 9% year-over-year in both the fourth quarter and full year 2024, reaching $1,345 million.

Improved Benefit Expense Ratio and MCR

Insurance benefit expense ratio improved to 82.8% and MCR to 73.5% in Q4 2024, showing strong improvements year-over-year.

Strong Financial Position

Ended Q4 2024 with $438 million in restricted and unrestricted cash and investments, providing a strong balance sheet position.

---

Clover Health Investments (CLOV) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CLOV Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
May 13, 2025	2025 (Q1)	-0.04 / -	-0.05	―	―	―
Feb 27, 2025	2024 (Q4)	-0.07 / -0.04	-0.146	72.60% (+0.11)
Nov 06, 2024	2024 (Q3)	-0.04 / -0.02	-0.086	76.74% (+0.07)
Aug 05, 2024	2024 (Q2)	-0.05 / 0.01	-0.06	116.67% (+0.07)
May 07, 2024	2024 (Q1)	-0.07 / -0.05	-0.152	67.11% (+0.10)
Mar 12, 2024	2023 (Q4)	-0.14 / -0.15	-0.176	17.05% (+0.03)
Nov 06, 2023	2023 (Q3)	-0.11 / -0.09	-0.158	45.57% (+0.07)
Aug 08, 2023	2023 (Q2)	-0.14 / -0.06	-0.219	72.60% (+0.16)
May 09, 2023	2023 (Q1)	-0.17 / -0.15	-0.16	5.00% (<+0.01)
Feb 28, 2023	2022 (Q4)	-0.24 / -0.18	-0.34	48.24% (+0.16)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

CLOV Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Feb 27, 2025	$4.14	$3.97	-4.11%
Nov 06, 2024	$4.35	$3.67	-15.63%
Aug 05, 2024	$1.88	$1.83	-2.66%
May 07, 2024	$0.74	$0.87	+17.57%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---